Magnolol.

Magnolol and honokiol are structural isomers that occur together in magnolia bark and both act as positive allosteric modulators at GABA-A receptors. Standardised extracts carry the pair because their actions overlap and add.

Valerenic acid and magnolol both act as positive modulators at the GABA-A receptor, though at different sites. Their calming effects on nerve signalling add together.

Passionflower flavonoids modulate the same receptor family that magnolol acts on. Combined use raises overall inhibitory tone more than either alone.

Kavalactones enhance GABA-A binding and also damp voltage-gated sodium channels. Stacked with magnolol the sedative signal is additive, so dosing is normally kept modest.

Theanine acts on glutamate transport and raises alpha wave activity while magnolol works through GABA-A. The two arrive at a settled state by separate routes.

Magnolol does not open the GABA-A channel on its own, it increases the response to GABA that is already present. Supplying more of the ligand and more modulation of it are complementary steps.

Melatonin acts on MT1 and MT2 receptors to shift circadian timing while magnolol lowers arousal through GABA-A. The mechanisms do not overlap, which is why the two are formulated together.

Rosmarinic acid in lemon balm slows the breakdown of GABA, leaving more of it at the synapse. Magnolol then amplifies the response to that larger pool.

Jujuboside saponins modulate GABAergic and serotonergic signalling and jujube is combined with magnolia bark in traditional calming preparations. The two overlap on the same inhibitory pathway.

Ashwagandha withanolides moderate the hypothalamic pituitary adrenal output and cortisol rhythm, while magnolol acts directly on receptor level inhibition. They address evening arousal from two different points.

Magnolol and rutin were each fed to broilers challenged with oxidised soybean oil and compared within one study, rather than being given together. Both are polyphenols with phenolic hydroxyl groups that quench radicals, so the pairing is chemically coherent rather than speculative, but it is not a tested combination. The data are from birds, not people, and describe tissue and serum antioxidant markers rather than a clinical outcome.

Magnolol is a lipophilic biphenol that partitions into membranes, the same compartment where alpha-tocopherol interrupts lipid peroxidation. Phenolic co-antioxidants of this kind spare one another by regenerating the phenoxyl radical back to the parent phenol. The relationship is chemical and mechanistic; it has not been read out as a clinical endpoint in humans.

After magnolol donates a hydrogen atom it is left as a phenoxyl radical at the membrane interface. Ascorbate in the aqueous phase reduces phenoxyl radicals, which is the same chemistry that regenerates tocopherol. This supports normal antioxidant recycling; it is not a measured outcome in people.

Animal feeding studies of magnolol report glutathione and glutathione-dependent enzyme activity among their serum and tissue readouts. Glutathione is the cell's main thiol buffer and works on quinone and radical species that phenolic compounds generate downstream. These are markers measured in birds and pigs, not clinical outcomes, and the co-occurrence is an association rather than a demonstrated causal pairing.

Cysteine availability sets the pace of glutathione synthesis, and NAC is a cysteine donor. Where magnolol chemistry draws on thiol recycling, cysteine supply is the upstream constraint. The logic is biochemical; no combination trial in humans is being claimed.

Alpha-lipoic acid cycles between its dithiol and disulfide forms and can reduce oxidised antioxidant species in both aqueous and lipid compartments. That amphiphilic reach complements a strictly lipophilic phenol like magnolol. This is mechanistic pairing logic, not a human trial result.

Ubiquinol works inside the inner mitochondrial membrane and the plasma membrane, terminating lipid peroxidation and regenerating tocopherol. Magnolol distributes into the same lipid phase because of its two phenolic rings and alkenyl side chains. Both act on membrane lipid oxidation markers; neither pairing has a clinical endpoint attached here.

Astaxanthin sits across the bilayer with its polar end groups at both surfaces, quenching singlet oxygen and peroxyl radicals. Magnolol acts in the same lipid environment through hydrogen atom donation. The two chemistries differ, which is the reason to place them together; the combination has not been measured in people.

Both magnolol and quercetin are substrates for glucuronidation and sulfation, so the two compete for the same conjugating capacity when taken together. That competition can raise circulating concentrations of the unconjugated forms of either. It is a pharmacokinetic interaction to formulate around, not a claimed benefit.

Curcumin and magnolol share a first-pass problem: extensive glucuronidation in gut wall and liver. Co-dosing loads the same conjugation enzymes, which changes exposure to both. Formulators pair them for that reason and because both need a lipid or surfactant vehicle to disperse.

Magnolol is a lipophilic neolignan with very low aqueous solubility, so its dissolution rate limits how much reaches the gut wall. Phospholipids form mixed micelles with bile salts and keep such compounds in a dispersed state through the small intestine. This is a delivery relationship, and it says nothing about what happens after absorption.

Taking a lipophilic phenol with dietary fat triggers bile release and micelle formation, which is how such molecules are presented to the enterocyte. MCT is a common carrier in soft-gel and liquid formats for exactly this reason. The claim is about dispersion and delivery, not about any downstream effect.

Phosphatidylcholine complexes are used to disperse phenolic plant compounds that otherwise crystallise out of aqueous media. Magnolol sits squarely in that class. Regard the pairing as a formulation choice, with the trade-off of added phospholipid mass per capsule.

Poultry and pig studies feeding magnolol measured intestinal microbiota composition and mucosal morphology in the same animals. Plant phenolics reaching the distal gut are substrates and selective pressures for resident bacteria, and bacterial enzymes in turn deconjugate phenolic glucuronides. The measurements are microbial community markers in animals, not human outcomes, and the direction of any human effect is untested.

Inulin is fermented to short-chain fatty acids by colonic bacteria, and those same populations carry the glucuronidases that release phenolics back into their free form in the lumen. Pairing a fermentable substrate with a phenolic is a plausible way to shape that compartment. This is mechanistic reasoning about the gut, not a measured combination result.

Glutathione peroxidase requires a selenocysteine residue to reduce hydroperoxides, and magnolol studies in birds and pigs report this enzyme among their antioxidant readouts. Without adequate selenium the enzyme cannot be made in full. The cofactor relationship is textbook; the enzyme activity is a marker rather than an outcome.

Cu/Zn superoxide dismutase needs both metals in its active site to dismutate superoxide. Magnolol feeding studies routinely report superoxide dismutase activity as an antioxidant marker. Adequate zinc status is the condition for that enzyme to function; it is not a claim that the pair does anything together.

The mitochondrial superoxide dismutase isoform carries manganese at its active site and handles superoxide generated at the respiratory chain. That is the compartment where lipophilic phenolics accumulate. The cofactor requirement is settled biochemistry and stands on its own.

Commercial magnolol is nearly always supplied as a bark extract standardised to magnolol plus honokiol rather than as an isolate. The two isomers differ only in hydroxyl and allyl positions and travel together through extraction. Anyone reading a label should check which of the two the standardisation figure refers to.

Magnolol is a documented positive allosteric modulator at GABA-A receptors, and apigenin from chamomile binds the benzodiazepine site of the same receptor family. Combining two allosteric modulators at one receptor complex produces additive effects on alertness. Flag this as an additive-sedation interaction to account for, not as a benefit claim.